Clinical Trial

Efgartigimod for the Treatment of Guillain-Barré Syndrome

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are: Will efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod? Participants will: On day 1 and day 5 of the treatment period, drug A was administered intravenously. Keep a diary of their symptoms
Trial Details
NCT Number NCT06885762
Lead Sponsor Zhongming Qiu
Conditions Guillain-Barre Syndrome (GBS)
Enrollment 20 participants
Start Date 2025-04-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-20